IndraLab
Statements
Hydroxychloroquine inhibits StopRA trial 164. 1 / 1
|
1
reach
"On the basis of the hypothesis that hydroxychloroquine might inhibit endolysosomal TLR signalling or processing of autoantigens for MHC class II dependent presentation, clinical trials are in progress, or in development, to examine whether hydroxychloroquine treatment of asymptomatic, autoantibody positive individuals can prevent or delay the development of RA (the StopRA trial 164; ClinicalTrials.gov : NCT02603146) and T1D (run by the T1D TrialNet consortium; C. Greenbaum, personal communication), respectively."